These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 17355742

  • 21. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.
    Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
    [Abstract] [Full Text] [Related]

  • 22. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012 May; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

  • 23. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [Abstract] [Full Text] [Related]

  • 24. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
    Pawaskar M, Zagar A, Sugihara T, Shi L.
    J Med Econ; 2011 Jan; 14(1):16-27. PubMed ID: 21158486
    [Abstract] [Full Text] [Related]

  • 25. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL, Sauriol L, Minshall ME.
    Appl Health Econ Health Policy; 2010 Jan; 8(4):267-80. PubMed ID: 20578781
    [Abstract] [Full Text] [Related]

  • 26. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.
    Gordon J, McEwan P, Sabale U, Kartman B, Wolffenbuttel BH.
    J Med Econ; 2016 Dec; 19(12):1167-1174. PubMed ID: 27356188
    [Abstract] [Full Text] [Related]

  • 27. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
    Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ.
    Adv Ther; 2007 Dec; 24(2):273-90. PubMed ID: 17565917
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
    Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ.
    Int J Clin Pract; 2008 Jun; 62(6):869-76. PubMed ID: 18479280
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B.
    Vasc Health Risk Manag; 2012 Jun; 8():255-64. PubMed ID: 22566747
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT, Thompson MF, Sauriol L.
    Pharmacoeconomics; 2007 Jun; 25(3):253-66. PubMed ID: 17335310
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
    Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N.
    BMC Health Serv Res; 2014 Sep 22; 14():419. PubMed ID: 25245666
    [Abstract] [Full Text] [Related]

  • 40. A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.
    Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJ.
    Adv Ther; 2012 Dec 22; 29(12):1051-66. PubMed ID: 23179373
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.